TD Cowen Reiterates Buy Rating on Abbott Labs (ABT)

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $130.00 price target on Abbott Labs (NYSE: ABT).

The analyst commented, "We expect ABT to post solid 2Q results that keep it on track to hit its 2024 guidance. ABT has multiple new products that are enhancing its growth from the Big Three. It also is regaining ground in the US baby formula market and has margin drivers from lower costs and better mix. While the NEC litigation remains an overhang, we think the risk is more manageable than recent stock weakness suggests."

For an analyst ratings summary and ratings history on Abbott Labs click here. For more ratings news on Abbott Labs click here.

Shares of Abbott Labs closed at $103.05 yesterday.

You May Also Be Interested In

• Ferguson Enterprises to Join S&P 500; ADI Global Distribution to Join S&P SmallCap 600
• Oceanfirst Financial (OCFC) Reports In-Line Q2 EPS
• General Dynamics wins $273 million in defense contracts